GlassScriptPhysician profile
Brandon Hays
NPI 1538842000
$4,485.06
in general payments reported to CMS, 2019-2025
30 companies · $3,638 in 2025
The $3,638 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $847 · 2025: $3,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,747 · Travel and Lodging: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.04 |
| Travel and Lodging | $738.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,332.55 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $523.32 | 2024-2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $346.61 | 2024-2025 | Mavenclad |
| Abbvie INC. | $293.20 | 2024-2025 | |
| Medtronic, INC. | $253.79 | 2025 | Percept PC Brainsense |
| Neurocrine Biosciences, INC. | $248.79 | 2024-2025 | Ingrezza |
| Ucb, INC. | $236.49 | 2024-2025 | Rystiggo, Briviact, Fintepla |
| Tg Therapeutics, INC. | $166.95 | 2024-2025 | |
| Lundbeck LLC | $120.76 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $107.84 | 2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $105.13 | 2025 | |
| Alexion Pharmaceuticals, INC. | $86.51 | 2024-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $75.17 | 2024-2025 | Ongentys, Crexont |
| Lilly USA, LLC | $69.33 | 2024-2025 | Kisunla |
| Celgene Corporation | $58.27 | 2024-2025 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $55.75 | 2025 | Tysabri, Vumerity |
| Acadia Pharmaceuticals INC | $51.62 | 2025 | Daybue, Nuplazid |
| Neurelis, INC. | $42.53 | 2025 | Valtoco |
| Amgen INC. | $40.36 | 2025 | |
| Cycle Pharmaceuticals INC | $38.41 | 2025 | Tascenso Odt, Bafiertam |
| Rgh Enterprises LLC | $37.61 | 2025 | |
| Boston Scientific Corporation | $34.03 | 2025 | Wavewriter Alpha Prime 16, Watchman |
| Orphalan INC | $31.77 | 2025 | Cuvrior |
| Axsome Therapeutics, INC. | $21.56 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $21.04 | 2025 | Zeposia |
| Eisai INC. | $18.91 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.53 | 2024 | Hyqvia |
| Banner Life Sciences, LLC | $17.96 | 2024 | |
| Janssen Biotech, INC. | $16.11 | 2025 | |
| Pfizer INC. | $14.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.